Related Experiment Videos

[Treatment of purulent meningitis in the child using Cefotaxime]

Pediatrie
|June 1, 1985
PubMed

Insights

Cefotaxime effectively treats gram-negative bacillary meningitis in children, including resistant strains. This antibiotic offers a reduced treatment duration and good outcomes for various bacterial meningitis cases.

Area of Science:

  • Infectious Diseases
  • Pediatrics
  • Pharmacology

Context:

  • Bacterial meningitis, particularly gram-negative bacillary meningitis, poses a significant threat to infants and children.
  • Cefotaxime demonstrates excellent penetration into the cerebrospinal fluid (CSF).
  • Ampicillin-resistant Enterobacteriaceae and Hemophilus influenzae are common causative agents of meningitis.

Purpose:

  • To evaluate the efficacy and safety of cefotaxime in treating meningitis caused by gram-negative bacilli in pediatric patients.
  • To assess the optimal dosage and administration of cefotaxime for pediatric meningitis.
  • To determine the impact of cefotaxime on treatment duration and patient outcomes.

Summary:

  • Cefotaxime was administered at 150 mg/kg/24 h via continuous infusion every 6 hours to 28 pediatric patients with gram-negative bacillary meningitis.
  • Excellent clinical outcomes were observed in 13 cases of Hemophilus influenzae meningitis and 7 cases of Enterobacteriaceae meningitis, with reduced treatment durations.
  • The study highlights the effectiveness of cefotaxime in treating complicated meningitis, including hydrocephalus and ventriculo-peritoneal shunt infections, emphasizing the need for drug monitoring.

Impact:

  • Cefotaxime offers a viable and effective treatment option for pediatric gram-negative bacillary meningitis, including resistant strains.
  • The study supports a potential reduction in the duration of antibiotic therapy for certain types of meningitis.
  • Findings underscore the importance of therapeutic drug monitoring for optimizing cefotaxime treatment in pediatric meningitis.

Related Concept Videos